Abstract: A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profi le. Several new treatments now focus on suppressing T-cell differentiation or T-cell infl ammation. Since infl ammatory bowel disease (IBD) represents a state of dysregulated infl ammation, drugs that augment the anti-infl ammatory response have the potential to downregulate infl ammation and thereby hopefully modify the disease. Tumour necrosis factor (TNF) is a major target of research and clinical investigation. TNF has proinfl ammatory effects in the intestinal mucosa and is a pivotal cytokine in the infl ammatory cascade. Certolizumab pegol (CDP870) is a PEGylated, Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody. PEGylation increases the half-life, reduces the requirement for frequent dosing, and possibly reduces antigenicity as well. Certolizumab has been shown in Phase III trials to achieve and maintain clinical response and remission in Crohn's disease patients. It improves the quality of life. Certolizumab pegol will be indicated for moderately to severely active Crohn's disease, but it is not yet licensed in Europe or the US. It is not possible to construct an algorithm for treatment, but when compared with infl iximab the two principal advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence of infusion reactions, and low rate of antinuclear antibodies), and a subcutaneous route of administration. These two factors may be suffi cient to promote it up the pecking order of anti-TNF agents.
Background
Crohn's disease is a chronic infl ammatory disease of the gastrointestinal tract which primarily affects younger individuals, although 15% of people are over the age of 60 at diagnosis. The natural history is characterized by relapses and remission. It causes patchy, transmural infl ammation, which can affect any part of the gastrointestinal tract, although it predominantly affects the distal small bowel (ileum, about 30%), colon (30%), or both (30%). Once established at a particular site, it rarely extends elsewhere (Sands 2004a) .
Classifi cation
In clinical practice Crohn's disease is defi ned by location of disease: terminal ileum, colonic, ileo-colic, perianal, upper gastrointestinal, or by the pattern of disease: infl ammatory, fi stulating or stricturing. For the purposes of classifi cation, the age of onset (<40 years, or >40 years) and modifi ers according to the presence or absence of perianal or upper gastrointestinal disease location have been included (Silverberg et al 2005) . Clinical activity at a point in time is classifi ed broadly into remission, mild, moderate, or severely active Crohn's disease Travis et al 2006) . These are not precisely defi ned entities. Most clinical trials in patients with active Crohn's disease recruit patients with a Crohn's Disease Activity Index (CDAI) >220. The fallibility of this threshold is illustrated by the high placebo response in recent trials of biological therapy (Su et al 2004) . Remission is widely accepted as a CDAI <150 and response to any therapy is generally defi ned as a decrease in CDAI >100 points. It would make sense to defi ne disease activity in groups of 100 points (remission CDAI <150; mild 150-250; moderate 250-350; and severe >350), and future trials may adopt this approach. To put this into clinical context, moderate disease activity is consistent with symptoms of intermittent vomiting, or weight loss >10%, where treatment for mild disease is ineffective, or a tender mass is present without overt obstruction. The Creactive protein (CRP) is usually elevated above the upper limit of normal. By contrast, severe disease may be manifest by cachexia (BMI <18 kg/m 2 ), evidence of obstruction or abscess, or persistent symptoms despite intensive treatment .
Prevalence
The incidence of Crohn's disease is generally estimated at around 5-10 per 100 000 per year, with a prevalence of 50-100 per 100 000, although this may be an underestimate (Loftus 2004) . It is considered to be up to twice as common as ulcerative colitis in adults, although prevalence of the two conditions in children is similar. It is estimated that up to 240 000 people are affected by infl ammatory bowel disease (IBD) in the UK (Carter et al 2004) .
Pathogenesis
The pathogenesis remains unknown, but is likely to be related to mucosal immune dysregulation, genetic factors, bacterial fl ora, and other as yet unidentifi ed environmental triggers. The complex interaction of genetic, microbial, and environmental factors culminates in a sustained activation of mucosal immune and non-immune responses, facilitated by defects in the intestinal epithelial barrier and mucosal immune system, resulting in infl ammation and cell destruction. In a healthy individual, the intestinal mucosa is in a state of controlled infl ammation regulated by a complex balance of proinfl ammatory (tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-1, IL-6, IL-8 and IL-12) and counterbalanced by anti-infl ammatory cytokines . Because infl ammatory bowel disease represents a state of dysregulated infl ammation, drugs that can augment the anti-infl ammatory response have the potential to downregulate infl ammation and thereby improve the disease. Cytokines play a central role in modulating infl ammation, and are therefore a target for IBD therapy using specifi c cytokine inhibitors, such as anti-TNF antibodies (Sands 2004b; Ardizzone and Bianchi Porro 2005; Chang and Lichtenstein 2006; Korzenik 2006) . TNF has diverse proinfl ammatory effects within the intestinal mucosa and is a pivotal cytokine in the infl ammatory cascade. TNF binds to cell receptors with high affi nity and specifi city. This transmembrane binding of TNF effects apoptosis of T cells, so a fundamental defect in Crohn's disease appears to be dysregulation of T cell populations (Ivashkiv 2003; Sands 2004b; Korzenik 2006) . The release of TNF is a crucial early step during innate immunity and the initial response to pathogens, through the induction of the acute infl ammatory response. Controlled infl ammation is generally benefi cial, but if there is too much TNF, or TNF is inappropriately produced, it provokes chronic infl ammation, such as in Crohn's disease. This is the premise behind anti-TNF therapy for Crohn's disease.
Conventional therapy
The principal aims of medical treatment are to decrease the inflammatory process, to induce clinical remission when disease is active by promoting mucosal healing, to maintain remission in patients and avoid complications. Conventional therapeutic recommendations for Crohn's disease are determined by the location, pattern, and severity of disease. The European Crohn's and Colitis Organisation (ECCO) recommend budesonide, a steroid with low systemic bioavailability, as fi rst-line treatment for active Crohn's disease . Budesonide 9mg daily is favored because it is superior to both placebo (OR 2.85, 95% CI 1.67-4.87) and mesalazine 4 g/day (OR 2.8, 95% CI 1.50-5.20) (Otley and Steinhart 2005) . It achieves remission in 51%-60% over 8-10 weeks Ivashkiv 2003; Sandborn 2003; Sands 2004b; Ardizzone and Bianchi Porro 2005) . Budesonide is preferred to prednisolone for mildly active CD because it is associated with fewer sideeffects, although a Cochrane systematic review has shown budesonide to be somewhat less effective (pooled OR for the 5 trials 0.69, 95% CI 0.51-0.95) (Otley and Steinhart 2005) . Although corticosteroids are effective in suppressing the symptoms, they do not promote mucosal healing and their use is limited by short-and long-term side effects. Patients refractory to or dependent on steroids are candidates for immune modifi er treatment with antimetabolites such as 6-mercaptopurine, azathioprine, or methotrexate . Immunomodulators (azathioprine/mercaptopurine, methotrexate) are effective in steroid-dependent Crohn's disease (NNT 3) (Pearson et al 2000; Alfadhli et al 2003) . Ileal resection is an alternative, but this should be individualized, according to disease characteristics. Infliximab is best reserved for patients not responding to initial therapy and for whom surgery is considered inappropriate. This does not mean that surgery takes precedence over infl iximab. Both the indication and timing are joint decisions between patient, physician, and surgeon. Surgical options should, however, be considered and discussed with the patient as part of an overall management strategy. The stage at which anti-TNF therapy is introduced may change if it can be established that earlier therapy alters the pattern of disease. The use of anti-TNF therapy such as infl iximab is governed by national guidelines, such as those from the National Institute for Health and Clinical Excellence (NICE) in the UK (NICE 2002) . These frequently fail to keep up with therapeutic trends and professional associations have published more recent, evidence-based guidance (Lichtenstein et al 2006a; Travis et al 2006) .
Shortcomings of conventional therapy
It has been estimated that 10%-20% of patients have severe Crohn's disease that is best treated with anti-TNF therapy, but there as been no systematic evaluation. In populationbased studies, 25% of all patients with Crohn's have active disease at any one time (Munkholm et al 1995 (Munkholm et al , 1997 , of which 10% will be severe enough to need hospitalization. However, looked at another way, around 50% of all patients with Crohn's disease need surgery, which increases to 80% of those with ileocecal disease (the commonest location) within 15 years of diagnosis. Since surgery will generally only be performed for severe disease not responding to medical therapy, the proportion of patients potentially treated with biologic therapy in the future is likely to be much higher. Even so, there is evidence of under-treatment with biologic agents, especially in Europe (Reddy et al 2005) . Alternative treatments are also needed for those who develop immunogenicity on infl iximab (estimated at 50% or more, depending on dosing schedule, concomitant therapy, and assay technique) (Vermiere et al 2003) . Safety is a crucial factor, with serious or life-threatening adverse events in about 2%-5% of patients given infl iximab, double the rate of sepsis in those receiving steroids, and myelotoxicty or risk of lymphoma in those receiving thiopurines (Kandiel et al 2005) . Furthermore, there is little evidence that current therapy changes the natural history or outcome of disease, although some preliminary evidence that early intervention with anti-TNF therapy reduces steroid exposure, reduces hospitalization of surgery in the short term, and promotes mucosal healing (Rutgeerts et al 2004; D'Haens et al 2006; Hommes et al 2006) . This sets the scene for further biologic agents, such as certolizumab pegol (CDP870).
Structure, components and activity of certolizumab Fab fragments
Over the last decade there has been increasing interest in the use of antibodies and antibody fragments as therapeutic entities. Antibody molecules have two main functions: to bind to antigen molecules and then to eliminate these from the body. The binding to antigen molecules is facilitated by an antigen-binding domain formed between the heavy-and light-chain variable domains. Within each antibody variable chain there are three regions known as complimentary determining regions or CDRs, The space formed by these CDRs enables the antibody molecule to bind its antigen. The interest in the use of antibody fragments, Fab and Fab', is in part due to their reduced size compared with an IgG molecule, which enables them to penetrate more rapidly into body tissues. An additional benefi t of these antibody fragments is that they lack an Fc region which fi xes complement and can promote undesirable side-effects, such as a cytokine release syndrome (Chapman 2002 ).
Immunogenicity
Fab fragments are generally less immunogenic than whole antibodies (13), but the concept of immunogenicity needs to be understood, since it is different to antigenicity. Antigenicity simply refers to the process by which an antigen (which can itself be an antibody) binds to a specifi c receptor and provokes an immune response that may be either immunogenic or tolerogenic. It is the immunogenic response (immunogenicity) that is potentially harmful to the recipient. Humanization of an antibody promotes homology with human proteins, which reduces their antigenic profi le, but even human proteins can be immunogenic in humans. Consider the antibodies that develop to recombinant Factor VIII or insulin. Consequently the concept that humanization of its own account reduces immunogenicity is false (Clark 2000) . Immunogenicity depends not only on the molecular conformation of the protein, but also on dose, delivery, frequency, concomitant therapy, and individual. The ability of polyethylene glycol (PEG) to reduce the immunogenicity of foreign proteins has been under investigation, with a view to the production of engineered monoclonal antibodies that are effective but less immunogenic (Clark 2000; Chapman 2002 ).
Implications of humanization
Humanization is a separate antibody engineering strategy that has tried to tackle the immunogenicity of therapeutic antibodies, but as indicated above is not the whole solution. Humanized antibodies can be generated where the antigenbinding CDRs are murine, while the rest of the antibody, including the antibody variable (V) region framework regions (FRs), is human. The problem is that during the humanization process, the antibody affi nity is frequently reduced. This reduction in affi nity might be minimized by careful selection of human FRs that are homologous to the original antibody, or by reintroducing the important murine FR residues back into the engineered antibody (Clark 2000) . Examples of humanized monoclonal antibodies include visilizumab (antiCD3, Nuvion 
Mass manufacture
The manufacturing of antibodies and antibody fragments is costly. A potential solution has been to express fragments of antibodies such as Fab' in microbial expression systems such as Escherichia coli. This is more economical and yields much higher amounts of protein as a result of large fermenter volumes and shorter fermentation times compared with mammalian cell fermentation. The problem here is that these antibody fragments have very short circulation times in vivo. This in turn can be overcome by conjugation to PEG which results in an increased half-life to proteins to which it is attached, either by avoiding renal clearance since polymer increases the apparent size of the molecule to above the glomerular fi ltration limit, and/or through evasion of cellular clearance mechanisms (Chapman 2002; National Horizon Scanning Centre 2004) . Half-life is increased progressively as the size of PEG is increased; values increase almost 7-fold for a single 25-kDa PEG chain, and 13.5-fold for a single 40-kDa PEG chain (Chapman 2002) .
Reducing immunogenicity
The potential benefi ts of PEGylation are (Chapman 2002 The other way to reduce immunogenicity is concurrent therapy with immunomodulators or pre-treatment with steroids (Baert et al 2003) . Whether concomitant immunomodulation is necessary with certolizumab pegol remains to be established. Combination therapy with azathioprine/mercaptopurine or methotrexate is recommended for infl iximab, but it is unclear to what extent this changes the risk:benefi t ratio (Lichtenstein et al 2006b) .
Mechanism of action and pharmacokinetics
Certolizumab pegol has been constructed by grafting the short, hypervariable complementarity-determining regions (CDRs) derived from the murine monoclonal antibody HTNF40 onto an otherwise virtually human immunoglobin . The Fab' fragment is linked to two crosslinked chains of PEG each of which has a molecular weight of 20 kDa. This site-specifi c polyethylene glycolation increases the half-life of the antibody fragment to approximately 2 weeks in plasma, thereby increasing the interval between dosing required dosing (Chapman 2002) . Certolizumab pegol is administered as a 400-mg subcutaneous injection, initially every 2 weeks for the fi rst three doses and subsequently every 4 weeks for maintenance. Subcutaneous administration of certolizumab pegol has been shown in Phase III trials to be clinically effective with good tolerability in patients with moderate-to-severe Crohn's disease and rheumatoid arthritis. It is possible that the subcutaneous route of drug administration could contribute to the good tolerability because peak serum concentrations are lower than would be achieved after intravenous delivery (National Horizon Scanning Centre 2004; Winter et al 2004; Schreiber et al 2005a Schreiber et al , 2005b . Certolizumab pegol is a Fab' fragment that has been designed not to fi x complement. It is possible that the absence of the Fc fragment, which is the reason that it does not activate complement-dependent cytotoxicity effector mechanisms, could enhance therapeutic safety and reduce adverse events compared with other anti-TNF agents. This has yet to be established in clinical practice.
Effi cacy and safety studies Effectiveness Initial studies
A dose-ranging, placebo-controlled, Phase II study evaluated subcutaneous doses of certolizumab pegol 100, 200, or 400 mg against placebo at weeks 0, 4, and 8 in 292 patients with active Crohn's disease (CDAI 220-450 points) (Schreiber et al 2005a) . Patients were assessed for effi cacy every 2 weeks up to week 12. The primary endpoint was the percentage of patients achieving clinical response at week 12 (a decrease in CDAI of >100 points) or remission (CDAI <150 points) in the intention to treat population. Onset of effect of certolizumab pegol was evident at week 2. The percentage of patients achieving response or remission was highest in the certolizumab pegol 400-mg treatment group at all times. The greatest percentage of patients meeting the defi nition of response or remission was observed at week 10 (certolizumab pegol 400 mg 52.8% vs placebo 30.1%, p=0.006). However, at week 12 (the primary endpoint) the difference between the certolizumab pegol-and the placebotreated groups was not statistically signifi cant (certolizumab pegol 400 mg 44.4% vs placebo 35.6%, p=0.278). In a posthoc analysis, however, when patients with baseline CRP concentration >10 mg/L showed clearer separation between active treatment and placebo (week 12, certolizumab pegol 400 mg 53.1% vs placebo 17.9%, p=0.005). This effect was achieved almost entirely by reducing the response and remission rates in placebo-treated patients. Health-related quality of life data was also evaluated at weeks 0, 2, 4, 6, 8, 10, and 12 using the Infl ammatory Bowel Disease Questionnaire (IBDQ). For all treatment groups, there was an improvement (increase) in IBDQ total scores within 2 weeks of treatment that matched the reduction in CDAI scores. In contrast to the overall CDAI scores, however, there were statistically signifi cant improvements in IBDQ scores for the certolizumab pegol 400-mg group compared with placebo at all time points (p<0.05) (Schreiber et al 2005a) . Clinically meaningful improvements in IBDQ total score (equivalent to a 16 point increase; Irvine et al 1994) were seen in 52.8% of patients receiving certolizumab pegol 400 mg at week 2, compared with 32.9% in the placebo group. This increased to two thirds (66.7%) at week 12, compared with half (50.7%) in the placebo group (National Horizon Scanning Centre 2004; Schreiber et al 2005a) . These data supported the anti-infl ammatory effect of certolizumab pegol. In contrast to the certolizumab pegol 400-mg group, clinical response and remission rates in patients receiving certolizumab pegol 200 mg and 100 mg were not generally signifi cantly different from rates in patients receiving placebo, irrespective of baseline CRP concentrations (Schreiber et al 2005a) . Certolizumab pegol 400 mg therefore appears to be the optimal dose.
Intravenous administration
In a single-dose, randomized, double blind, placebo-controlled, multicenter, exploratory Phase II trial, certolizumab pegol 1.25, 5, 10, 20 mg/kg, or placebo was administered intravenously to 92 patients with moderate to severe Crohn's disease (CDAI 220-450 points) (Winter et al 2004) . Although intended for subcutaneous administration, certolizumab pegol may also be effective for the treatment of Crohn's disease when administered intravenously. By administering certolizumab pegol intravenously, it was possible to explore the use of higher doses than is possible to deliver subcutaneously. The dose 5 mg/kg intravenously is approximately equivalent to a 400-mg subcutaneous dose of certolizumab pegol. The primary endpoint of the study was the percentage of patients achieving clinical response (defi ned as a decrease in CDAI>100 points) or remission (CDAI=150 points) at week 4 in the intention to treat population. A high placebo Dinesen and Travis response rate of 52%-60% was observed and there were no statistically signifi cant differences in the clinical response rates for any of the certolizumab pegol-treated groups compared with placebo. However, at 2 weeks after infusion, remission was induced in 47.1% of patients administered 10 mg/kg certolizumab pegol, compared with 16% of the placebo group (p=0.041). Remission was maintained at week 4, but at week 12 the remission rate was similar to the placebo group (23.5% in the certolizumab pegol 10 mg/kg group vs 32.0% in the placebo group). Interestingly, no additional clinical benefi t was observed with the higher dose of certolizumab pegol 20 mg/kg (Winter et al 2004) . The possibility that certolizumab pegol is less effective in patients with Crohn's disease when administered as an intravenous infusion rather than subcutaneously cannot be ruled out.
Subsequent studies
The PRECiSE clinical program is composed of 4 Phase III studies (PRECiSE 1, 2, 3, and 4). PRECiSE 1 is a placebocontrolled induction and maintenance study for which there is no comparable trial with infl iximab or other anti-TNF agent; PRECiSE 2 is an open-label induction and maintenance study, broadly similar in design to the ACCENT I study; and PRECiSE 3 and 4 are 24-month open label trials assessing the longer-term safety and tolerability of certolizumab, and have yet to report.
PRECiSE 1 randomized 659 patients with moderate to severely active Crohn's disease, to certolizumab pegol 400 mg or placebo at weeks 0, 2, and 4 and then every 4 weeks from week 8 to 24. The co-primary endpoints were response (ΔCDAI>-100 points) at week 6 and at weeks 6 and 26 . The overall results showed response at week 6 in 35.2% (certolizumab pegol) vs 26.8% placebo, and at weeks 6 and 26 in 23.1% and 16.0% respectively (all intention to treat, p<0.05). Remission rates were signifi cant at week 4 (19.5% vs 11.3%, certolizumab pegol vs placebo p<0.01), but not at weeks 6 (21.6% vs 17.2%), or weeks 6 and 26 (14.4% vs 9.8%) respectively. The outcome did not differ if the baseline CRP was >10 mg/L (37.2% vs 26.0% response at week 6, 21.5% vs 12.3% at weeks 6 and 26). In a post-hoc analysis to allow some comparison with the initial placebo-controlled infl iximab study in moderate to severe Crohn's disease, the response to a lower standard of effi cacy (ΔCDAI >-70 points) at 4 weeks was 44.0% vs 33.7% (p<0.01) for certolizumab pegol vs placebo. This indicates that certolizumab pegol is effective at inducing remission in active Crohn's disease.
PRECiSE 2 evaluated the effi cacy and tolerability of subcutaneous certolizumab pegol 400 mg every 4 weeks to maintain clinical response in patients with moderate to severe Crohn's disease after open-label induction (UCB 2005; Schreiber et al 2005b) . 668 patients with active Crohn's disease (CDAI 220-450) who had responded to induction therapy with certolizumab pegol 400 mg subcutaneously at week 0, 2, and 4 (decrease in baseline CDAI score >100 points at week 6), were randomized to maintance therapy with certolizumab pegol 400 mg or placebo every 4 weeks up to week 24. Patients were stratifi ed according to baseline CRP (CRP <10 mg/L or CRP >10 mg/L). After open label induction, 64.1% of patients (428 of 668) achieved a clinical response. After the randomized phase at week 26, the clinical response rate in the CRP >10 mg/L was 61.6% for the certolizumab pegol group vs 33.7% for the placebo group (p<0.001). This was no different to the overall response: at the end of 26 weeks clinical response was maintained in 62.8% for certolizumab pegol vs 36.2% for placebo (intention to treat, p<0.001). Furthermore, signifi cantly more of the patients in the certolizumab pegol group were in clinical remission (CDAI <150 points) at 26 weeks compared with placebo (47.9% vs 28.6% respectively, p<0.001) (Schreiber et al 2005b) .
Safety General
All anti-TNF agents have the potential to cause serious or life-threatening events, including sepsis, opportunistic infections, or neoplasia. In a systematic review of pooled data from 9 prospective clinical trials of 3493 patients with rheumatoid arthritis treated with adalimumab or infl iximab, the odds ratio (95% confi dence interval) for serious infection compared with 1512 controls was 2.0 (1.3-3.1) (Bongartz et al 2006) . For certolizumab pegol, the overall incidence and pattern of adverse events reported were comparable across all treatment groups in PRECiSE 1 and 2 and the majority of events were of mild or moderate intensity. The most frequent adverse events included headache, nausea, nasopharyngitis, dizziness, arthralgia, abdominal pain not otherwise specifi ed, and pyrexia.
Serious adverse events
For serious non-Crohn's disease related infections in PRECiSE 2, there were 6/216 (2.8%) in the certolizumab pegol group and 2/212 (0.9%) in the placebo group. This included 1 case of tuberculosis in the certolizumab pegol group and 1 pneumonia (none in placebo). For malignancies, there were 4 malignancies in PRECiSE 1 (in 662 patients) 2 with placebo and 2 with certolizumab pegol, but none in PRECiSE 2 (668 patients) or the dose-ranging study (292 patients). There have been 2 deaths in the three studies (1 each in PRECiSE 1 and 2, neither thought to be associated with certolizumab pegol) (Winter et al 2004; Schreiber et al 2005a Schreiber et al , 2005b Sandborn et al 2006) . In both PRECiSE studies, injection site (erythema and pain) adverse events were more common in the placebo-treated patients, while in the dose-ranging 292 patient study, reactions occurred in 2.7%-6.8% of patients for both the placebo and the 400-mg dose. Antinuclear antibodies developed in 8 patients on certolizumab pegol and 2 on placebo, with anti-double stranded DNA antibodies in 1 patient in each group, but were transient (<26 weeks) in all but 2 patients. There were no meaningful effects of certolizumab pegol on hematology and biochemical measurements or urinalysis data.
Comparison with other anti-TNF therapy
It is very diffi cult to compare these data with those for infl iximab or adalimumab, because the patient exposure for infl iximab is vastly greater than for certolizumab pegol. Furthermore, concomitant medication, comorbidity, and the source of reporting differ widely. Nevertheless it does appear that certolizumab pegol may be less immunogenic than infl iximab. It seems unlikely that it will be associated with a lower risk of sepsis, tuberculosis, or neoplasia, since these are more likely to be generic than drug-specifi c adverse events.
Patient-specifi c implications (quality of life, satisfaction, convenience) Satisfaction
Patient compliance and satisfaction with treatment are important factors in managing chronic conditions, such as Crohn's disease. Evidence is accumulating to show that patient education significantly improves disease outcomes in chronic illness (Moser et al 1995; Caprilli et al 2006) . Nonetheless, surveys reveal that patients still feel insuffi ciently informed and would like greater involvement in their treatment, especially when assessing disease activity, its consequences, and the risks of therapy (Sands et al 2006) . It is important to discuss patients' worries and concerns, not only regarding their physical problems but also their emotional needs, which for some will require psychosocial counseling to improve quality of life (Moser et al 1995; Van Der Eijk et al 2004) . Changes in disease activity cause signifi cant psychological distress over time and are closely related to increases and decreases in anxiety and depression scores in IBD patients.
Convenience
The convenience of subcutaneous administration of certolizumab pegol (compared with intravenous infusion with infl iximab) will appeal to patients, but is likely to have a major impact only when self-administration becomes possible. At present it needs to be administered by a health care professional, although patients have shown themselves adept at self-administration of more complex interventions (such as immunoglobulin infusions) when trained. There also seems little doubt that the convenience of 4-weekly dosing will appeal compared with daily ingestion of drugs, even though concomitant prescription of immunomodulators will be recommended until there is more clear evidence that this is unnecessary.
Measures of quality of life
Although disease severity indices are traditional outcome measures for trials in Crohn's disease, a major limitation of these indices is that they do not provide a detailed picture of the patient's subjective function, including emotional and social problems associated with IBD. The importance of measuring subjective aspects of health status, referred to as health related quality of life, has become increasingly recognized. Goals of therapy for patients with IBD are to control symptoms, reduce complications, minimize treatment toxicity, and improve quality of life (Mitchell et al 1998; Guyatt et al 1989; Irvine et al 1994; Bernklev et al 2004; Travis et al 2006) . Quality of life, a subjective quantitative measure of health perception and function, embraces not only the physical but also emotional and social domains; these are referred to as health-related quality of life (HRQOL). Several different questionnaires are available to measure HRQOL. The Infl ammatory Bowel Disease Questionnaire (IBDQ) is the most extensively validated of the quality of life instruments related to IBD with specifi c questions regarding quality of life in Crohn's disease and ulcerative colitis patients (Guyatt et al 1989) . It has been evaluated in clinical trials and observational studies of patients with either Crohn's disease or ulcerative colitis (Mitchell et al 1998; Guyatt et al 1989; Irvine et al 1994; Bernklev et al 2004) .
Certolizumab and quality of life
A good understanding of the key predictors of quality of Schreiber et al 2005a) . However, the key test and outcome measure of interest for patients, doctors, health care organizations, and policy makers is the demonstration that biologics such as certolizumab pegol reduce hospitalization, surgery, and time off work. These are robust outcome measures for which there is no comparable substitute; mucosal healing is a potential surrogate marker, but has yet to prove a clear correlation (Rutgeerts et al 2004) . It is likely that mucosal healing correlates closely with improvements in quality of life, but this cannot be taken for granted. Reduction in surgery or hospitalization will undoubtedly be associated with improved well being.
Conclusion and place in therapy
The management of infl ammatory bowel disease must look at aspects other than drug therapy, dose and timing to achieve its therapeutic goals. The goals are induction of remission, maintenance of remission, limitation of side effects and avoidance of complications. Certolizumab pegol as a 400-mg subcutaneous injection, initially every 2 weeks for the fi rst 3 doses and subsequently every 4 weeks for maintenance has been shown to be well tolerated and effective. The clinical effect of certolizumab pegol is comparable to infl iximab, which is itself comparable to adalimumab (Colombel et al 2006; Hanauer et al 2006; Panaccione et al 2006; Schreiber and Sandborn 2006) . It seems probable that all anti-TNF agents will have similar effi cacy. The effect of certolizumab pegol is independent of CRP; although it is simply good practice to ensure that active disease is confi rmed (by CRP, endoscopy, or other objective measure) before instituting any anti-TNF therapy.
Certolizumab pegol will be indicated for moderately, as well as severely active Crohn's disease (Winter et al 2004; Schreiber et al 2005a Schreiber et al , 2005b ), but is not yet licensed in Europe or the US (license application submitted to the FDA March 2006). It is not possible to construct an algorithm for treatment, but when compared with infl iximab the two principal advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence of infusion reactions, and low rate of antinuclear antibodies), and the subcutaneous route of administration. These two factors may be suffi cient to promote it up the pecking order of anti-TNF agents, but cost will also be a consideration and self-administration has yet to be established. Comparative trials between biologics are desirable. Trials in infl iximab-intolerant patients, early treatment strategies, and withdrawal trials to determine the duration of therapy are essential. Essential too is the need to demonstrate an impact on the natural history by showing a reduction in hospitalization and operations for Crohn's disease. This is the acid test of biological therapy.
